LTP LTR Pharma Limited
—Mkt Cap: —P/E: —1d ago
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value41.69M USD
Revenue (TTM)500.30K USD
Gross Profit100.75K USD
Net Income (TTM)-3.87M USD
Revenue/Share0.0040 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU0000305294
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-4.31
EV/Revenue83.32
P/S115.82
P/B4.14
EPS (TTM)-0.08
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-1218.41%
EBITDA Margin0.00%
Profit Margin-3837.01%
ROE-17.75%
ROA-17.37%
Growth
Revenue Growth-38.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.49M USD
CapEx (TTM)9.10K USD
FCF Margin-899.86%
FCF Yield—
Net Debt-13.59M USD
Net Debt/EBITDA1.41
Balance Sheet
Debt/Equity—
Current Ratio34.36
Quick Ratio33.10
Book Value/Sh0.11 AUD
Cash/Share0.11 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.182.27M
Float106.82M
Insiders41.93%
Institutions0.00%
Technical
SMA 500.4782 AUD
SMA 2000.4767 AUD
Beta2.20
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)219.23K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—